Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein As a Hot Antiviral Drug Target

Overview

Journal Curr Top Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2017 Feb 28

PMID 28240183

Citations 42

Authors

Yanmei Hu

Hannah Sneyd

Raphael Dekant

Jun Wang

Affiliations

Soon will be listed here.

Abstract

Prevention and treatment of influenza virus infection is an ongoing unmet medical need. Each year, thousands of deaths and millions of hospitalizations are attributed to influenza virus infection, which poses a tremendous health and economic burden to the society. Aside from the annual influenza season, influenza viruses also lead to occasional influenza pandemics as a result of emerging or re-emerging influenza strains. Influenza viruses are RNA viruses that exist in quasispecies, meaning that they have a very diverse genetic background. Such a feature creates a grand challenge in devising therapeutic intervention strategies to inhibit influenza virus replication, as a single agent might not be able to inhibit all influenza virus strains. Both classes of currently approved anti-influenza drugs have limitations: the M2 channel blockers amantadine and rimantadine are no longer recommended for use in the U.S. due to predominant drug resistance, and resistance to the neuraminidase inhibitor oseltamivir is continuously on the rise. In pursuing the next generation of antiviral drugs with broad-spectrum activity and higher genetic barrier of drug resistance, the influenza virus nucleoprotein (NP) stands out as a high-profile drug target. This review summarizes recent developments in designing inhibitors targeting influenza NP and their mechanisms of action.

Citing Articles

Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches.

Bonomini A, Mercorelli B, Loregian A Cell Mol Life Sci. 2025; 82(1):75.

PMID: 39945883 PMC: 11825441. DOI: 10.1007/s00018-025-05611-1.

Evaluation of Safety, Immunogenicity and Cross-Reactive Immunity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, in Older Adults.

Jacobs B, Leroux-Roels I, Bruhwyler J, Groth N, Waerlop G, Janssens Y Vaccines (Basel). 2025; 12(12.

PMID: 39772052 PMC: 11728545. DOI: 10.3390/vaccines12121391.

Analysis of the interaction of influenza a virus nucleoprotein with host cell nucleolin.

Mishra S, Pandey A, Verma J, Rajala M Arch Virol. 2024; 170(1):1.

PMID: 39636515 DOI: 10.1007/s00705-024-06189-y.

Drug resistance and possible therapeutic options against influenza A virus infection over past years.

Asif Raza M, Ashraf M Arch Microbiol. 2024; 206(12):458.

PMID: 39499323 DOI: 10.1007/s00203-024-04181-3.

Endosomal fusion of pH-dependent enveloped viruses requires ion channel TRPM7.

Doyle C, Busey G, Iobst W, Kiessling V, Renken C, Doppalapudi H Nat Commun. 2024; 15(1):8479.

PMID: 39353909 PMC: 11445543. DOI: 10.1038/s41467-024-52773-w.

References

Vigerust D, McCullers J . Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respir Viruses. 2009; 1(5-6):189-92. PMC: 4941887. DOI: 10.1111/j.1750-2659.2007.00027.x. View

Wharton S, Belshe R, Skehel J, Hay A . Role of virion M2 protein in influenza virus uncoating: specific reduction in the rate of membrane fusion between virus and liposomes by amantadine. J Gen Virol. 1994; 75 ( Pt 4):945-8. DOI: 10.1099/0022-1317-75-4-945. View

Ma C, Soto C, Ohigashi Y, Taylor A, Bournas V, Glawe B . Identification of the pore-lining residues of the BM2 ion channel protein of influenza B virus. J Biol Chem. 2008; 283(23):15921-31. PMC: 2414288. DOI: 10.1074/jbc.M710302200. View

Martin K, Helenius A . Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import. Cell. 1991; 67(1):117-30. DOI: 10.1016/0092-8674(91)90576-k. View

Dong G, Peng C, Luo J, Wang C, Han L, Wu B . Adamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations. PLoS One. 2015; 10(3):e0119115. PMC: 4358984. DOI: 10.1371/journal.pone.0119115. View

Das P, Deng X, Zhang L, Roth M, Fontoura B, Phillips M . SAR Based Optimization of a 4-Quinoline Carboxylic Acid Analog with Potent Anti-Viral Activity. ACS Med Chem Lett. 2013; 4(6):517-521. PMC: 3733392. DOI: 10.1021/ml300464h. View

Du J, Cross T, Zhou H . Recent progress in structure-based anti-influenza drug design. Drug Discov Today. 2012; 17(19-20):1111-20. PMC: 3459301. DOI: 10.1016/j.drudis.2012.06.002. View

Wang G, Chen L, Xian T, Liang Y, Zhang X, Yang Z . Discovery and SAR study of piperidine-based derivatives as novel influenza virus inhibitors. Org Biomol Chem. 2014; 12(40):8048-60. PMC: 4177008. DOI: 10.1039/c4ob01079e. View

Govorkova E . Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses. Influenza Other Respir Viruses. 2013; 7 Suppl 1:50-7. PMC: 4942988. DOI: 10.1111/irv.12044. View

10.

Di Trani L, Savarino A, Campitelli L, Norelli S, Puzelli S, DOstilio D . Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol J. 2007; 4:39. PMC: 1878474. DOI: 10.1186/1743-422X-4-39. View

11.

Ooi E, Chew J, Loh J, Chua R . In vitro inhibition of human influenza A virus replication by chloroquine. Virol J. 2006; 3:39. PMC: 1481635. DOI: 10.1186/1743-422X-3-39. View

12.

Taubenberger J, Morens D . The pathology of influenza virus infections. Annu Rev Pathol. 2007; 3:499-522. PMC: 2504709. DOI: 10.1146/annurev.pathmechdis.3.121806.154316. View

13.

Weber F, Kochs G, Gruber S, Haller O . A classical bipartite nuclear localization signal on Thogoto and influenza A virus nucleoproteins. Virology. 1998; 250(1):9-18. DOI: 10.1006/viro.1998.9329. View

14.

Monod A, Swale C, Tarus B, Tissot A, Delmas B, Ruigrok R . Learning from structure-based drug design and new antivirals targeting the ribonucleoprotein complex for the treatment of influenza. Expert Opin Drug Discov. 2015; 10(4):345-71. DOI: 10.1517/17460441.2015.1019859. View

15.

Shibata M, Aoki H, Tsurumi T, Sugiura Y, Nishiyama Y, Suzuki S . Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine. J Gen Virol. 1983; 64(Pt 5):1149-56. DOI: 10.1099/0022-1317-64-5-1149. View

16.

Mata M, Satterly N, Versteeg G, Frantz D, Wei S, Williams N . Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor. Nat Chem Biol. 2011; 7(10):712-9. PMC: 3329801. DOI: 10.1038/nchembio.645. View

17.

De Clercq E . Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006; 5(12):1015-25. PMC: 7097821. DOI: 10.1038/nrd2175. View

18.

Chenavas S, Crepin T, Delmas B, Ruigrok R, Slama-Schwok A . Influenza virus nucleoprotein: structure, RNA binding, oligomerization and antiviral drug target. Future Microbiol. 2013; 8(12):1537-45. DOI: 10.2217/fmb.13.128. View

19.

Nguyen H, Trujillo A, Sheu T, Levine M, Mishin V, Shaw M . Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States. Antiviral Res. 2012; 93(3):381-6. DOI: 10.1016/j.antiviral.2012.01.006. View

20.

Paine P, Moore L, Horowitz S . Nuclear envelope permeability. Nature. 1975; 254(5496):109-14. DOI: 10.1038/254109a0. View